Cite
HARVARD Citation
Rodríguez-Otero, P. et al. (n.d.). P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY. HemaSphere. pp. 22-23. [Online].